Server is temporarily unavailable
Main category: colorectal cancer
Also included in: cancer / Oncology;  MRSA / drug resistance
Article date: 09 Sep 2011 - 0: 00 PDT window.fbAsyncInit = function() {FB.init({_appId:_'aa16a4bf93f23f07eb33109d5f1134d3',_status:_true,_cookie:_true,_xfbml:_true,_channelUrl:_'http://www.medicalnewstoday.com/scripts/facebooklike.html'});}; (function() {var s = document.createElement('script'); = true e.async; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e);}()); email to a friend printer friendly opinions

Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug. Jamming those circuits with targeted therapies may heighten or restore the drug's potency, according to a study published in science translational medicine.

The research focused on the drug cetuximab, on antibody that interferes with cancer cell growth by blocking a structure known as the epidermally growth factor receptor (EGFR). Cetuximab is effective in many patients with colorectal cancer or squamous cell cancer of the head and neck, but the benefits rarely last than a longer year, and some patients receive no benefit from the drug.

Until now, scientists haven't known why cancers that initially respond to cetuximab become resistant to it, or how to overcome such resistance.

In the new study, researchers led by Pasi Janne, MD, PhD, of Dana-Farber and Kimio East, MD, PhD, formerly of Dana-Farber and now at Kinki University School of medicine, Osaka, Japan, found that in some cetuximab-resistant cancer cells, a protein known as ERBB2 was actively sending "grow" signals, circumventing the "stop growing" signals triggered by cetuximab. The researchers discovered that ERBB2's activity jumped from an oversupply of the protein's parent, HER2/neu gene, or by a related protein, ERBB3, when prompted by high levels of the protein heregulin. In both cases, the new growth messages are unaffected by cetuximab.

"ERBB2 activates a critical signaling pathway that is not normally blocked by cetuximab, and in this way, subverts cetuximab's function," says Janne, the study's co-senior author with Kazuhiko Nakagawa, MD, PhD, of Kinki University. "Because ERBB2 isn't of affected by cetuximab, this is an easy way for cancers to become resistant to the drug."

The findings suggest that combining cetuximab with ERBB2-inhibiting drugs could be an effective therapy for cancers that are cetuximab-resistant from the start become resistant over time or for those that, the study authors say. Several such have already been approved inhibitors, while others are undergoing clinical study.

"We hope the findings of our study will inspire the development of clinical trials aimed at overcoming cetuximab resistance," East remarks. "We've identified biomarkers that can be used to select cetuximab-resistant patients who may benefit from a combination of cetuximab and ERBB2 inhibitors."

Janne estimates that up to 40 percent of colorectal cancers are cetuximab-resistant when first diagnosed. He notes that although the ERBB2 pathway may be responsible for many cases of cetuximab resistance, there are undoubtedly other pathways, yet to be discovered, that play a similar role. Further research is needed to confirm ERBB2's role, cetuximab resistance and to develop strategies for testing ERBB2 inhibitors and cetuximab in clinical trials.

Funding for the study which provided by grants from the national institutes of health, the American Cancer Society, the William Randolph Hearst Foundation, and the Hazel and Samuel Bellin research fund.

Article adapted by medical news today from original press release.

Visit our colorectal cancer section for the latest news on this subject.

Co-authors of the paper include Kreshnik Zejnullahu, Dalia Ercan, Andrew Rogers, Juliet Philips, MS, Jason Sun, Takafumi Okabe, MD, PhD, Jeffrey Swanson, MD, and Ramesh Shivdasani, MD, PhD, Dana-Farber; Isamu Okamoto, MD, PhD, Taroh Satoh, MD, Masayuki Takeda, MD, PhD, Yasuhito Fujisaka, MD, Toshio Shimizu, MD, PhD, Osamu Maenishi, Hiroyuki Itoh, MD, Kiyotaka OKUNO, MD, Minoru Takada, MD, Masahiro Fukuoka, MD, and Kazuto Nishio, Aichi, MD, PhD, Kinki University, Osaka, Japan; Federico Cappuzzo MD, Massimo Roncalli, MD, Annarita DESTRO, PhD, and Instituto Clínico Humanitas, Rozzano, Italy; John Souglakos, MD, PhD, University of Crete, Heraklion, Greece; Yonggon Cho, and Marileila Varella-Garcia, University of Colorado Cancer Center, Denver; Koichi Taira, MD, and Koji Takeda, MD, Osaka City General Hospital, Japan; and Eugene Lifshits and Jeffrey Engelman, MD, PhD, Massachusetts General Hospital.
Dana-Farber Cancer Institute please use one of the following formats to cite this article in your essay, paper or report:

APA
Dana-Farber Cancer Institute (2011, September 9). Overcoming resistance to targeted cancer drug. Medical news today. Retrieved September 9, 2011 from http://www.medicalnewstoday.com/releases/234064.php MLA
Dana-Farber Cancer Institute. "Overcoming Resistance To Targeted Cancer Drug". Medical news today, September 9, 2011. Web. 9 Sep, 2011.

Please note: If no author information is provided, the source is cited instead.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact our news editor

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send press any medical news or health news releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

Peliculas Online